Sunshine Biopharma Inc.
Extracted from this filing and checked against the source text.
Sunshine Biopharma Inc. amended Warrant Agent Agreement with Equiniti Trust Company valued at Amendment to Warrant Agent Agreement reducing exercise price to $0.11 and eliminating prohibition on (effective 2023-10-18).
On October 18, 2023, Sunshine Biopharma, Inc. (the “Company”) entered into an amendment to the Warrant Agent Agreement, dated February 17, 2022 (the “Warrant Agent Agreement”), between the Company and Equiniti Trust Company to (i) reduce the exercise price of the outstanding warrants issued by the Company on February 17, 2022 to $0.11, subject to further adjustment as provided therein, and (ii) eliminate the provision under the Warrant Agent Agreement that prohibits the Company’s chief executive officer, Dr. Steve N. Slilaty, from exercising his voting rights under his Series B Preferred Stock of the Company.View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.